Viewing Study NCT03798132


Ignite Creation Date: 2025-12-24 @ 9:27 PM
Ignite Modification Date: 2025-12-30 @ 5:23 PM
Study NCT ID: NCT03798132
Status: UNKNOWN
Last Update Posted: 2019-01-09
First Post: 2019-01-07
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Peritoneal Carcinomatosis Extent Evaluation: Radiologic, Laparoscopic and Pathologic.
Sponsor: Shimaa Abdalla Ahmed
Organization:

Study Overview

Official Title: Imaging Evaluation of Peritoneal Carcinomatosis Extent
Status: UNKNOWN
Status Verified Date: 2019-01
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: pathologically proved ovarian cancer patients that underwent contrast enhanced abdomino-pelvic CT and diagnostic laparoscopy before cytoreductive surgery (CRS) will be included in the study. Calculation of PCI (peritoneal cancer index) using Sugarbaker's method, peritoneal carcinomatosis extent will be categorized into low, moderate and large. Agreement in general and in each category between CT, laparoscopy, surgery and pathology will be assessed using kappa agreement.
Detailed Description: we will search medical records of primary ovarian cancer patients underwent CT abdomen, laparoscopy followed by cytoreductive surgery to calculate peritoneal carcinomatosis extent by each modality.

Regional PCI was calculated in each of the 13 anatomical abdominopelvic regions, then total PCI by summation of the lesion size score, it ranged from 0 to 39. Categorization of peritoneal carcinomatosis was classified into 3 categories low if PCI \< 10, moderate if 10-20, and large if \>20.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: True
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: